<SEC-DOCUMENT>0000914121-12-000461.txt : 20121018
<SEC-HEADER>0000914121-12-000461.hdr.sgml : 20121018
<ACCEPTANCE-DATETIME>20120918121642
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000914121-12-000461
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20120918

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANGIODYNAMICS INC
		CENTRAL INDEX KEY:			0001275187
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				113146460
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		14 PLAZA DRIVE
		CITY:			LATHAM
		STATE:			NY
		ZIP:			12110
		BUSINESS PHONE:		5187981215

	MAIL ADDRESS:	
		STREET 1:		14 PLAZA DRIVE
		CITY:			LATHAM
		STATE:			NY
		ZIP:			12110
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<html>
<head>
    <title>an26757785-corresp.htm</title>
    <!--Licensed to: Cadwalader-->
    <!--Document Created using EDGARizer 2020 5.4.3.1-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>&#160;</div>

<div style="TEXT-ALIGN: center"><img src="angiodynamics-logo.jpg" alt=""><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">September 18, 2012</font><br>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">VIA EDGAR</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Securities and Exchange Commission</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Division of Corporation Finance</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">100 F Street N.E.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Washington, D.C. 20549</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Attn: Martin James</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Re:&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline">AngioDynamics, Inc.<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> </font></font></font></div>

<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Form 10-K for the Fiscal Year Ended May 31, 2012</font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;&#160;</font></font></font></div>

<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Filed August 14, 2012</font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></font></font></div>

<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">File No. 000-50761&#160;</font></font></font></div>

<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Form 8-K dated July 12, 2012</font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></font></font></div>

<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Filed July 12, 2012</font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></font></font></div>

<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">File No. 000-50761</font></font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Dear Mr. James:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">AngioDynamics, Inc. (&#8220;AngioDynamics&#8221; or the &#8220;Company&#8221;) is submitting this letter in response to the written comments of the staff (the &#8220;Staff&#8221;) of the Securities and Exchange Commission (the &#8220;Commission&#8221;), dated September 4, 2012 (the &#8220;Letter&#8221;), with respect to AngioDynamics&#8217; Form 10-K for the fiscal year ended May 31, 2012, filed with the Commission on August 14, 2012 (SEC File No. 000-50761) and AngioDynamics&#8217; Form 8-K filed with the Commission on July 12, 2012 (SEC File No. 000-50761).&#160;&#160;Set forth below are the headings and text of the comments raised in the Letter, followed by our responses thereto.</font><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Form 10-K for the fiscal year ended May 31, 2012</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Item 8. Financial Statements and Supplementary Data</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Note C. Acquisitions, Acquisition of Navilyst, page 83</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Comment</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">You disclose that you valued the 9.5 million common shares issued as consideration for the acquisition of Navilyst using the closing price of your common stock the day prior to the date you completed the acquisition.&#160;&#160;Please tell us how you applied ASC 805-10-25-6 through 7 and ASC 805-30-30-7 which states that consideration issued for a business combination should be valued at its acquisition-date fair value.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div><br>
</div>

<div>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div style="WIDTH: 100%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">14 Plaza Drive, Latham, NY 12110, USA &gt; tel: +1 800-772-6446 or +1 518-795-1400 &gt; fax: +1 518-795-1401</font></div>
</div>

<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>
</div>

<div><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Company Response</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">AngioDynamics acquired Navilyst Medical effective 12:01 a.m. on May 22, 2012.&#160;&#160;Accordingly, we believe the most relevant stock price to value the approximately 9.5 million common shares issued as consideration for the acquisition is the closing stock price on May 21, 2012, the date closest to the consummation of the acquisition.&#160;&#160;The closing stock price on May 21, 2012 was $12.44, and the consideration shares were valued at that price.&#160;&#160;For informational purposes, the closing stock price on May 22, 2012 was $12.42.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Form 8-K dated July 12, 2012</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibit 99.1</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Comment</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In future filings, please revise to reconcile EBITDA to net income (loss) rather than operating income (loss).&#160;&#160;Note that operating income (loss) would not be considered the most directly comparable GAAP financial measure because EBITDA makes adjustments for items that are not included in operating income.&#160;&#160;Refer to Question 103.02 of the Compliance &amp; Disclosure Interpretations on Non-GAAP measures located at http://sec.gov/divsions/corpfin/guidance/nongaapinterp.htm.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Company Response</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In future filings, we will reconcile EBITDA to net income (loss) rather than operating income (loss).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In connection with our responses to the Letter, the Company acknowledges that:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company is responsible for the adequacy and accuracy of the disclosure in the filings;</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filings; and</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Please feel free to contact the undersigned at 518-795-1608 if you would like to discuss any of these issues.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Sincerely,</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">/s/ D. Joseph Gersuk</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">D. Joseph Gersuk</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Executive Vice President and Chief Financial Officer</font></div>

<div>&#160;</div>

<div style="TEXT-ALIGN: center">2</div>

<div>
<hr style="COLOR: black" noshade size="2">
</div>

<div>&#160;</div>

<div>&#160;</div>

<div><br>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>angiodynamics-logo.jpg
<TEXT>
begin 644 angiodynamics-logo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``34T`*@````@`!`$:``4`
M```!````/@$;``4````!````1@$H``,````!``(```$Q``(````0````3@``
M``````!@`````0```&`````!4&%I;G0N3D54('8U+C`P`/_;`$,``@$!`@$!
M`@("`@("`@(#!0,#`P,#!@0$`P4'!@<'!P8'!P@)"PD("`H(!P<*#0H*"PP,
M#`P'"0X/#0P."PP,#/_;`$,!`@("`P,#!@,#!@P(!P@,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(`"@!
M!0,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/W\KR#]O;]I.^_9#_9'\9_$/3-,M-7U+0((%M+:ZD9(&FGN8K9'
MDV_,R(TP<H"I<(5#)G</PD_:,_X.?OVDOB7K;77A*_\`"OPJT2QGN98H=.TJ
M#4)Y;=F!B6ZGOEE5WB1<>9#'`&+N2F-JIX[\6_\`@NU\6OVN?@E'X#^(^N^%
M_'EEINM)X@CU**UM['4K=Q$;6.$FU"0>1F=L9A\PR2J/,QM2OW?%_1YXGPM"
M-:O4H*I+:DZJ51ZVTYDH/Y3_`!T+X%XGX>K<0X2.=.2P<:D75ER2DO9Q?-)-
M0O.S2:;2ND[]#K?B/^T=X]^+GQ3B\;^(_%_B#5?%EK.+BTU.2\=9]/99FF06
MQ4@6Z)*[,B1!50GY0M?3_P"R-_P7-^+_`.SIY.F^*I_^%I>&TS^XUJZ9-4AS
MYK?N[[#N<R2*3YZS82)43RQS7Q_^P-^W7\*?@K^TKI/B/XQ?#2X\>>#K:SNX
MGTQ!#>BUNF5#;W?V>8I#=%<2Q^5*RJAF6929(8Q7Z6?%[_@D!\'?VO?@A:_$
M/]D;Q=H]W96.GLK:*NJSZG#JUT1%<)"]S=3M-8W8AF(:&X'5H%9;?#NWP?$O
M`^?9$D\XP<J4&VE)V<;K3>+:7EKJM8W6I_H1C_'CP<XFQL.%L73A5PKC#DJ\
MG+"#DMEI"K1Y;I.24>5N2ERI-O\`1#]CO]L3PA^W!\(3XS\&#58;"&^ETVZM
M=2MA!=6=Q&%8HX5G0YCDB<%'88D`)#!E7U2OYK_V:?VCO''[!7[0J^)M$M/L
M/B30OM6EW^DZM%<10R[E:*2WNH4>-SLD"OL8C;+"A(RF*_?S]B_]K'0_VU/V
M>M$\>Z)#]@^W[[>_TU[F.XFTJ[C;;)`[(?\`=="P1FBDB<HF_:/BZU'DU6Q_
M/'CEX'U^#,0LRRYNKE]5VC+1N$G=J$M;M65XSM9K1V>_JE%%4O$OB73O!GAW
M4-8UC4++2=(TFVDO+Z^O)U@MK."-2\DLDCD*B*H+,S$``$D@"LHQ<FHQ5VS^
M>F[:LNT5Y'X:_P""@'P&\9^(M/T?1_C;\(M6U?5KF.SL;&S\8:=/<WD\C!(X
MHXTF+.[,0JJH))(`!)KT_7_$NG>%+&.ZU74++3;66Y@LTFNIUAC>>>9(((@S
M$`O)-)'&B]6=U4`D@'KQ.78O#SC3KTI0E+9.+3?HFM2(5H33<9)V[,NT5Y'X
ME_X*`?`;P9XBU#1]8^-OPBTG5])N9+.^L;SQAIT%S9SQL4DBDC>8,CJP*LK`
M$$$$`BO3_#7B73O&?AW3]8T?4++5M(U:VCO+&^LYUGMKR"10\<L<B$JZ,I#*
MRD@@@@D&C$Y=B\/"-3$4I0C+9N+2?HVM0A6A-M1DG;LR[17D?B7_`(*`?`;P
M9XBU#1]8^-OPBTG5])N9+.^L;SQAIT%S9SQL4DBDC>8,CJP*LK`$$$$`BKND
M_%_X=?MF?#KQAX=\`?%31-:\_39-.O\`4_`_B6UN=1T'[5%+''/'+`TGV><;
M9&B=A]Z+(!VD5O+)L;3BJV(HSA3TO)PE9)M*][>>G<A8BFWRQDF^UT>GT5\6
M?\$/OV.?"7[&G[.OBO1O`_QST3XX^']7\1M>M>:)'9+IVEW0M8$DB!@EG<SL
MBPLX><J%$.V.,EWE^A/B)^VY\%_A#XQO/#OBSXN_##POX@T[9]JTS5_%-C97
MEMO19$WQ2RJZ[D=&&0,JP(X(-=V;9!['-*V7Y7*6)C!Z25.<&UIJZ<ES1LW9
MI]>NJ,Z&*YJ,:M9*#?2Z?XK1GI]%8OP[^)/ASXO>#K/Q%X3U_1/%'A_4=_V7
M4](OHKVSN=CM&^R6)F1MKHZG!.&4@\@BN7^+'[6_PI^`GB*#1_'7Q.^'O@O5
M[FV6\AL==\16>G7,L#,Z+*L<TBL4+(ZA@,$HPSD&O(I8#$U:SP].G*4U>\4F
MY*V]U:^G7L;RJP4>=M)=^AZ%17XL_#O]I/\`X6]_P=?6=]X3\??\)1X,U'37
MT>UN-(US[;IES8IX8:Z>U1HG:)H%OT>8Q@E1.I<C>":_7_X3_&[P7\>_#L^L
M>!?%_A?QII%M<M9S7VA:K!J-M%.JH[1-)"S*'"NC%2<@.IQ@BOJ^,.",3D"P
MKJMS]M0I5G[K7)[3F2A*]]5RO5VOVT.'+\RABN>RMRRE'?>UM5]YT]%<QX[^
M-W@OX6^(O#VC^)_%_A?PYJ_BVY^QZ'8ZIJL%G<ZS/NC3RK:.1@TS[I8EVQAC
MF1!C+#/+^+/VW/@OX"\W^W?B[\,-%\C4KK1Y/M_BFQMO+OK7R_M5J=\HQ/#Y
MT7F1GYD\U-P&X9^7H99C*RBZ-&4N;:T6[VNG:RUV?W,[95Z<;\TDK>9Z?17%
M_!_]I/X=?M"_VC_P@'C[P5XX_L?R_M__``C^N6NI_8O,W^7YOD.VS?Y<FW=C
M=L;&<&CXP?M)_#K]GK^SO^$_\?>"O`_]L>9]@_X2#7+73/MOE[/,\KSW7?L\
MR/=MSMWKG&12_L[%_6/JGLI>T_EY7S;7^&U]M=MM1^VAR\_,K=[Z?>=I17%_
M!_\`:3^'7[0O]H_\(!X^\%>./['\O[?_`,(_KEKJ?V+S-_E^;Y#MLW^7)MW8
MW;&QG!K$UW]MSX+^%O[:_M/XN_##3O\`A&]271]7^U>*;&'^R[YO.VVL^Z4>
M5.?LUQB-\,?(EX^1L6LIQSJRHJC/GC:ZY7=7M:ZM=7NK=[H3KT[*7,K/S/3Z
M*\P\%_MN?!?XD?VM_P`([\7?AAK_`/8&FS:QJ?\`9WBFQNO[.L8<>;=3>7*?
M+@3<NZ1L*NX9(R*/AW^VY\%_B]XQL_#OA/XN_##Q1X@U'?\`9=,TCQ38WMY<
M[$:1]D44K.VU$=C@'"J2>`35SR7,(J3E0FN57E[LM%:]WIHK:Z]!+$TG:TEK
MMJCT^BOA+_@ME^RYX<_:9_X5-_PD7[4&B?LX?\(EJ5YK&F?VC=Q0?VO?)]F\
MJZA\R]M<3V?S;9%WLGVPX*;CN^T_B)\2?#GPA\'7GB+Q9K^B>%_#^G;/M6IZ
MO?165G;;W6--\LK*B[G=%&2,LP`Y(%=F+R:G#`X3$X>JZE2NYIP]G-<KC)1B
ME)KEJ.=[^Y?E>DM69T\0W5J0E&RC;6ZUNKO3=6\]]T;5%>8?#O\`;<^"_P`7
MO&-GX=\)_%WX8>*/$&H[_LNF:1XIL;V\N=B-(^R**5G;:B.QP#A5)/`)K;^,
M'[2?PZ_9Z_L[_A/_`!]X*\#_`-L>9]@_X2#7+73/MOE[/,\KSW7?L\R/=MSM
MWKG&17!/*<=&O'#2HS522NH\KYFM=4K7:T?W/L:JO3<7-25EUOH=I17%_!_]
MI/X=?M"_VC_P@'C[P5XX_L?R_M__``C^N6NI_8O,W^7YOD.VS?Y<FW=C=L;&
M<&BN7$8:K0J.E7@XR6Z:::Z[/7;4N$XR7-%W1_,%K_@G2/V%O^"W=WX?\6V"
M>$?"GPF^-%CJ\4'VEM0:P\/+JD&I:=.?*:25P-/>!]I+RG:5<&3>H_;3_@XV
M_P"3(O"W_8\6G_I!J%?)'_!TS_P2ZUS6?%.F?M2_#OP\^HVVDZ0VF?%"VT^-
M/M`LX,-::SY$<8><P(9(;F9I)'CMX[8K&(H9I$^,O@W_`,%4?$GQ(_8DM_V>
M/&^F)XXTK3[RUO\`P/XBEU.2*[\+)`C[H"JJPO(#`TD4*NR^2LK`%U2%(OZ'
MSC!XCCKA3#Y]0JJ>,R^$H8B,FN>5*-Y1J7=F[+F;YFW)\UKR5I?1^!^84<C\
M2,LI5HM4JV(IJ%EHI3:A:VR7-)7MLNAQOBCP'\&G^!/Q.\0^-(_$"_$>TN]"
MB\&1:#K$%A)=S3PZLMU)?0RI(+BRC2WM#(R1&8.EK$DT"S,]?HQ_P:._!;QI
MI.C?%_XA7]EX@TCP%X@_L_2-%EE2V73_`!/=6TEU]JGCW(;D_9&98%D1TA9[
MBZ1EED@_<_!?P+_8:T;]N+]I[PYH/BKXE>'_`(4>!;>UDN_$VNZCJ4-G=O:1
M21@6FGF8>5]LF,K`/(2L2+))LD*"-_T]_:L_X+0>%/V5_AOI/P;_`&9].M)-
M/\"V,?ABUUR\W7NG:?96MJEO;K8,\K/=/&0`)Y]T9\C.VX64./C<1QO&AP5#
MA7!.4IUIN==R;<8J,VZ=.">BTC"<I1MK[MWJH_MWBKX*<2\2^+^82RS"6A+D
ME&=N6G:5*'-.4[6^)R5M9-WLF]ZO_!QC\./A=HUWX4\1VDMI9?%_6)UCO;2V
M;#ZEI212*+JY0*0'25(HHY&*LZ^8O[P0CRN;_P"#;C3_`!T/CM\0+ZRM;M?A
MC+H8M=6NC!&+>36HYX'LXED8;VD2VFO69(R559HC(`7@)^<OV,_V(/BG_P`%
M2?C+=:Q=ZGJ=]H&GZA9Q>+?%NM:E*UPT0:%9+6VFDCF,]^MI\T:.ICC41&5D
M5XEE_=SX`?`#PE^R[\)=*\"^!=*?1?"VBM.UG9M>3WC1&>>2XE)EG=Y&+2RR
M-\S'&[`P``/RFK4T]E%[;O\`1?K]WI^A>*G%N#X/X(CX90Q'UW%-)59O6-)*
M2FH15V[Q:BH1=^5:NVD%V-?-W_!6>+X-:Q^PUXIT+X\>-+WP)\._$=S8V=SJ
M.GMG4'G2[BN88K:,0SM(Y:WRRI"Y$22MA51G7Z1KX%_X.#/^"=GQ"_X*`_LS
M^%HOAG+>ZIXD\&:T;P^&VU>.QL=9@FC\IY2LNV)[J`[3&TDD86*6\`+-(JGZ
MK@&CA*O$6#CCL2\-352+=5-)P<=4TY)QB^9)<TDU'=JR/X?S252.$J.G#G=G
MIWOZ:O3HMS\6/VCM5_8IF_9[OK'X2:9^TC%\2;>Y\_3M0\5MI!T^Z1Y+99(;
MH6[DA(X8[AHC%&KF6<^8SH$$?N_[;?@O_A8?_!NW^R5\1-9U;6]1\0>%_$>K
M^%;/[1=>=$;&XN=1PC;P7_<II-I%$%8*D89=I&S9BP_LU_M3_M:_`G3/@_H/
M[&7@KP5-H6FVGVGQ6WPYC\,Z]JT-H(XOWNJZDZ(T\KF.23R"DTI5_P#ED95/
MI][^R?\`M%?'#_@WXM_`&I_"?6]&O?@W\1HK_1M'DT?4XO$OB"QG6Z,[+8-;
MDR>7<:L&65&"M%%<`JC6^Z?^X,QS3"4)9>_KD7.CC(RESXB%6:IU*=2ENK-1
MDY?#T5W>RT_-J-"<O:_NW:5-I6@XJZ:E]ZMN'[+O_!%KX1?&+_@A[KOQ^U:^
M\:I\0(_#FO>)(&M]1A2SMY-*?5(X[=8C"<P3>3`TNXM)NA7RY(E9U;M?^"9'
M[8/CO]E;_@W'^-GCKPMJN_Q!X*\:OIGA]M1!O(-&CNSH\;F&)SL78][<3JA!
MC,SEG1PSJWVG^Q_^Q_X[\!?\&_#_``CN]*W_`!`U_P"'/B"*VTEB;66.ZU5;
MZXM[27[0(_)G7[7'%()-JI(KC<57<?GO_@D)_P`$V?$?QR_X(L_&#X(?$[1_
M&OPLO?&OC6>ZMGU/1I;.\@\JVTF:WN1!<*AE@^T6H5@"N]4D171OF7\GS#C7
M"YEALQ>=XE5L/2S*DXQDU*U!5'?ECNX.":T6JOU;/=I9=.C.C]6ARSE1E=K3
MWK=7WN>8?\$A/^#?OX1?MF?L%Z1\3OB!K_C6;6_'?VV.SBTBYALHM!CMM1,`
M=-\<GG3M]DF!:3,?EW941"2-)J\O_P""$_\`RCK_`."@?_9.4_\`39KU=1^S
M'^TU_P`%!_\`@E[\+(?@MI7[.U[XHTCPO<RSV4T_@W4-<CM$N2+EH8KS3)A;
MS)YDLCD[I'5Y70L`@C2E_P`&[WP\UGXO?L8?MR>$_#MG_:/B#Q1X*M-(TRU\
MU(?M-U<6.N111[Y"J+N=U&YF"C.20,FOL,\KYL\JSO'9GC85\+.OA9T'&I&<
M84OK,7TTBN3DWT=F[O5OS\-&A[?#4Z--QFHS4KIIM\C^_6_WG4?\$L_VG/%7
M['/_``;J_'[XB>"9K*V\4Z'X^:#3[BZMQ<1VKW46A6AF$9^5GC6=G0.&3>J[
ME=<H=K_@E1_P0?\`AG^W_P#L76_QF^*_B[XA:YXQ^*-SJ-P;BUU".&337BU-
MHWN"\J2M<W4K6LY>2;*%+QAY7F(L]>A?\$A/^";/B/XY?\$6?C!\$/B=H_C7
MX67OC7QK/=6SZGHTMG>0>5;:3-;W(@N%0RP?:+4*P!7>J2(KHWS+Y'\'/C/_
M`,%!_P#@D1X`M_@CHWP,LOB+X;T&YNKK1M4L_"VH>(+;[--<RL1'<:?+&`CS
M":98[E%N5$XW*JF-%\/,<QJXFOF^#X7QM.AF$L8IN3G&#GAU3248S::DE4NW
M%/17OI*SZ:-%0CAZF-IN5)4[6LW:5]VNFG7_`",3_@CO\=O&G_!/+XS_`+:G
MPHT?5++Q-I'PG\)^)_$]B=1AG2VGU70I_LL<XMTGVQ)<JX\Y5)D800*)0(\D
M_P""0'_!,+3O^"S$/Q4^.W[07BGQ1XCO]0UJ31;:2QU);:YEO?L.9IYE,!54
M@6YL3:QQ,L2FW:-XC"JQM[O_`,$<?^"1WQ)\0_\`"^OB=^T7;ZWX:\0?'_PY
M?>'C;13VMOJ,MKK'^DZC>S6Z1,EK.7,(BC;:T;+<+);@".O(_A1\%/VY/^"$
M5]X]T/X9_#JR^,OP[\2:U;BPOXK&[UF.1UAE*W46FV=VMQ:/)'MCN'DC9-]M
M"@E=1$TG3FF?83%8S-<+P_CJ-/,ZBPZ]KS1@JG+&*JJG5T5[VNE9NVVEU%#"
MU(4Z$\73DZ*Y_=LW:[?+>.YQ/["O[(^G?L*?\'-?A_X5Z/J][KND>&+G46L;
MR\B6.Y:"Y\,W-W'')L^5GC6<1LZA0Y0L$0-L7MO^"0'B5/\`@EE_P6T^*G[/
M/B#4+W2?"WC*YDT71QJ$]C(UU/&_VK1)[FX!7:\UC/*BQQ8+SWT2-$&`$>)\
M'?@#^V%X9_X*W_!+]I;XA_"Z]OM1^*VM03ZK_9^C3SVWA33KE1I4D-[##\]B
M]OITJ21FX8D`(96DECN8T[7_`(.<_P!GOQ!^S[^TQ\*OVH?!)LM*NH[FTTNZ
MO(+&V$EKK5C(]W87<N\DW3R0HR#?$RHFFHK,0Z(.O,,=3SC-J7#N/Q5.M]?P
M$:,IQDI1>*H3J2YKI6LIN36BN[<MG9.*5)X>A+%TH./LJKDDU9\DDE;[K?J4
MO`VH6O\`P5]_X.3'U[3/$7VOX?\`P0\G4]+GBDMT:YM=&GB""UDA25+B";5[
M@SAW8,]K,^'C81HOS;^PC_P27\%_M9_\%9_BY\#=5\2>*-*\$?#"YU]DGM3`
MVJZC!8ZDEA!&9FC,4;DS1R._DL&$;*$3>&3],/\`@V+_`&/[K]GS]A2^\=:W
MI7]G>(/B[J2ZG"SFX2=]'MT,=B)(I`J+N=[R='C!$D-U"Q=AM5.*_P""5O[%
M_P`5/@W_`,%SOVH/'GBCP1K>B>#-7_MS^SM9N45;/4O[1UFWOK3[/)G$^ZWB
M=G\O=Y+`)+Y;D(?%K\>1RNKG.691B52IX'"TZ-'6*<ITY<LII=9.4Y*ZNWH]
M&].B.5NNL/6Q$.9U)N4M]$U=+TLD?,/Q[_9.\.?\$I/^"_\`^SSHOP?O=;TW
M3/%>I:1?20ZC-%?_`&&'5-6N]-NK.%GCW>1]DW1JTA>9=Q;S2^&'H7_!8W2O
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MJ<*7N>T6\6U'W=TEWVOMTZH\B_8*_:2^&?P)_P""VGPX\0?`&V^(5K\-O'&M
M0^')M`\0S1V-S9)JCFT:V:2&:X%W:V\TD%S&)2'8P1HV7C%PW4?M&_\`!._P
MY^T'_P`'('BOX)R:]K>E>'_&?B.7Q!J-\JQ37B?:-*_MR[AB.U47<[RQ1LRO
MY:LC,)2I#TO$W[%'[7'B_P",_P`*OVC-&_9N\+^#[]/%EC;:%X+\->$UT*VT
MJ>QGCE@N+^P4I-!:SSK-NN;F4$"-MTD,+6I;[@_X8O\`BI_Q%'?\+5_X0C6_
M^%;_`-F_VK_PDFQ?[.\G_A&_[+V>;G;Y_P!K^3R/]=M_>[/*_>5]#G7$F$P&
M-JYE@\9!5?[.Q$+^UA4G[:C.+IJ3VE43E))VO-J7Q)7.7#8.I5IQHU*;Y?;1
M?PM+EDG=KLM%Z:;'P_\`\'#7_!,#X>_\$\OBGX!UCX9B]TKPW\1;:]4^'YYI
M+J/29[$6JO)%<2NTKI,+E6*2%BCHY#E76.+T+_@N=_P1:^$7_!.?]D3P9XT^
M']]XUGUN?Q'!X;O#J^HPW,5_'+#J-V;AU2%-LX\J&$>64C\N(9C,A>1OI'_@
MYY_9.^)G[6'B+]GK2OAMX$\4>,[J*YUNUN7TNPDFMM/>X;2UA-S.!Y5LC%'_
M`'DS(@".2P"L1Z[_`,'*W[.7CO\`:3_X)_Z)I_P_\*:WXQU/0/&MEJ]Y8:1;
M&ZO%M?LE[;&1($S)+B6YA!6-68*Q<@(CLOR?#OB/F$\/PK'$X]WJ3KJO>:O)
M1J*%/VMW?;1.6LGK=O4[L7E%)2QSA2V4>739M7=O^!L?"/\`P<0_$36?B]^Q
MA^PWXL\17G]H^(/%'@J[U?4[KRDA^TW5Q8Z'++)LC"HNYW8[54*,X``P*ZC_
M`(.#OB9J7[87_!5/X4?LU:=XXO;#PLESHFEZG8K:,UMI.M:G=,GVMXSY?VIT
ML;FT9?WA5!)(BM&SS9Z?_@LM_P`$Z_C9\6OV,/V)_"?A;X>:WXB\0>!O#D?A
M3Q!:Z<T5S_9%_-8Z5$BS.CE$@#VEP&N2WD1[`7D4.A;T_P#X+Z_\$W_C9\6/
MVBOA]^T;\$8_[?\`$'PWTVWA?2+6&)]1T^2PNKG48+^".8E+SYY"AMU1I"RQ
M!8YA(PCUX8S[),/_`&)!XBE"4%F*IMRCRTYSK+V3EI)13C?EORIIJS:]USC,
M+B9_67R2:?L6]'=I1]ZVU]=]_P!3M=/_`.#7;]G_`,.ZIX=U/0?&/QJ\-ZWX
M;V2P:IIGB"TAO);I+AYX[LN;0^7.FZ-%,`C4+!&VWS-\C_G5_P`%*9].\"?\
M%M/&,W[7EI\0O&_@..Y^UZ%#X;NEM&.BES/IUM`L\<2RVJKYEK.L$D#>>;J1
M;AI4<R_5GPL_X*;?\%(OCY\8?"/AJQ_9[T3P=]LU+_2+[7/`FMZ7H_D^1*K?
M;;FYG/EP)N$W[DK,[P1HGF;S#+VG_!13X_?M]?`W]I+XAWGA[X1Z)\4_@+XA
MQX?T?PVVBP^*;.>WEM8_,FE@M!#J/[P1SB1;@-;HUP\0,H\F1O/X:QG%&7YU
M['/L;0Q$ZE&HHWQ485(*4X75.HHR:G*UXQ^%J+U7+8UQE/!5<-S86G*"4E?W
M&T[)[JZT75[Z^9\P_LN?L#_\$W?VIO!TNIV_Q]^)_@.]M,?:M(\;>(M$T*\M
M]SRJF&EM/(GW"+>?L\LNQ7CW[&8+17A'B_\`X)3_`+5W[=GC_7OB)H_[--E\
M.K74+F*U;0=/L;7P;I]F\-M"A-M87T\<H1P`[2*&1Y6EPV0RJ5^B8JEA'4<I
M<6.@W9NG*OAY.#:3<>;2]G=)VVMON_)A*I;3`\WFHR5_.VI_397YN?%;_@UB
M_9;\7_'B[^(_A/3/$OPZUJ2TO3!H^B:DR>'8]0N$N=EZ;3`E41/.C"UM[B"V
M*VT<?E>69%<HK^`HR:V/US!8RMA,13Q6'ERSIR4HOM*+NG\FKGY+?&?X?ZU^
MSQXSUOP]XVTZX\.:SX<E,.H6MT`&A;`(((R'5@59&0LKJZLI8,"?N+_@E[_P
M17U_]HW5-4\1_''PQXU\!^"[+R#HVF3E--U'Q(XN'$XG1C]JLX%6`H5:.*65
M;M)(I8]F6**,3B)NLJ5[+EOZWNK>GI9^=C_03QZ\6N(<LX7RV>6S5&>-I0E.
M44U*+E%2:@VWRKI?626SOJ?L'\&/@QX6_9W^%NB>"?!.B67ASPMX<MA:Z?I]
MJI$<*9+$DDEG=F+.\CEG=W9V9F8D]/114122LC_/:K5G4FZE1MR;NV]6V]VW
MU;"BBBF9A1110`52\2Z5/KOAW4+&UU*]T6ZO+:2"'4+-87N;%V4JLT8F22(N
MA(91)&Z$@;E89!**J,G%J2Z?/\&)J^A^3>D_\$M_^"C'PO\`^$PT;PO^U?HF
MK^'_`!%YEDMYX@U_4[K46M1YJ1RQ&>SN7T^=DD+,;6<,K;<2.8T<?3W_``1C
M_P""1_\`PZQ^'7BK^T_%_P#PEGBWQ_\`V?+J_P!EMOL^G:=]EBEVP0;LR2XE
MN;C,S[/,7ROW,15MQ17Z%GGBAG6:8"KEM54J=.JXNI[.E"#J.%G'G<5=\K2:
MV[;:'E8;)</1JQK1YFXWM>3=K[VOW/M.BBBOSL]8****`"OQT^)/_!OK^U'^
MUI\1=?LOC-^U/_;?@634KC5],/F:AJGF71E98I/[)D:"TLLPRS?+!*ZP[O*0
M,A+`HKZ_A/CC-.&YU:N5.$9S2]Z4(3E&U[.+DGRO5WZ/2Z=E;@QV6T<8HQKW
M:71-I/UMN?K)\$?A/IWP$^#'A#P+H\][<Z1X+T6ST*QFO'5[F6"U@2"-I&15
M4N50%BJJ"2<`#BNGHHKY6O6G6J2JU'>4FVWW;U;.V,5%**V04445D4%%%%`!
21110`4444`%%%%`!1110!__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
